CN108486038B - 一种构建脂肪干细胞膜片的方法及应用 - Google Patents
一种构建脂肪干细胞膜片的方法及应用 Download PDFInfo
- Publication number
- CN108486038B CN108486038B CN201810235273.2A CN201810235273A CN108486038B CN 108486038 B CN108486038 B CN 108486038B CN 201810235273 A CN201810235273 A CN 201810235273A CN 108486038 B CN108486038 B CN 108486038B
- Authority
- CN
- China
- Prior art keywords
- adipose
- cells
- derived stem
- cell membrane
- endometrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 43
- 239000012528 membrane Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 37
- 239000001963 growth medium Substances 0.000 claims abstract description 29
- 210000005168 endometrial cell Anatomy 0.000 claims abstract description 27
- 230000006698 induction Effects 0.000 claims abstract description 18
- 230000002357 endometrial effect Effects 0.000 claims abstract description 17
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 17
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 14
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 12
- 210000001519 tissue Anatomy 0.000 claims abstract description 9
- 108010081589 Becaplermin Proteins 0.000 claims abstract description 8
- 238000003501 co-culture Methods 0.000 claims abstract description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 7
- 210000000981 epithelium Anatomy 0.000 claims abstract description 7
- 229960005309 estradiol Drugs 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- 239000012894 fetal calf serum Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 238000010008 shearing Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 6
- 108060005980 Collagenase Proteins 0.000 claims description 6
- 229960002424 collagenase Drugs 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000411 inducer Substances 0.000 claims description 6
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims 6
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 abstract description 10
- 108020004999 messenger RNA Proteins 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000001172 regenerating effect Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 7
- 108010076876 Keratins Proteins 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002346 layers by function Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 210000000438 stratum basale Anatomy 0.000 description 3
- 208000028685 Asherman syndrome Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 2
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 2
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000001389 adhesions of uterus Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100030695 Electron transfer flavoprotein subunit alpha, mitochondrial Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010061401 Uterine injury Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
Abstract
本发明涉及脂肪干细胞膜片,特别是一种构建脂肪干细胞膜片的方法及应用。属于组织工程与再生医学领域。该方法包括如下步骤:步骤1)选择脂肪干细胞作为种子细胞构建细胞膜片;步骤2)将子宫内膜细胞用于诱导的共培养细胞;步骤3)采用化学诱导和共培养的方式构建脂肪干细胞膜片。本发明利用细胞膜片培养基添加外源性因素(TGF‑β1,EGF,PDGF‑BB,17‑β雌二醇)复合子宫内膜细胞共培养,诱导人脂肪干细胞成膜,这个膜片培养体系,诱导成的膜片各上皮标记mRNA表达量上调,免疫荧光显示蛋白CK18表达阳性,提示部分干细胞向上皮细胞转化。这个体系诱导出的膜片在修复子宫内膜上皮方面更有效。
Description
技术领域
本发明涉及脂肪干细胞膜片,特别是一种构建脂肪干细胞膜片的方法及应用。属于组织工程与再生医学领域。
背景技术
正常的子宫内膜分为基底层和功能层,功能层在雌孕激素的作用下发生周期性脱落,脱落后由基底层再生,如果基底层损伤,则子宫内膜功能层无法再生,胶原大量沉积,出现不可逆性瘢痕修复,造成宫腔粘连。
90%的宫腔粘连的发生与妊娠或者非妊娠时子宫遭受机械性损伤有关,其中与妊娠相关的清宫术是导致宫腔粘连的主因,世界卫生组织(WHO)统计,全球每年有4000万妇女进行人工流产,中国每年人工流产达1400万人次,排世界第一位宫腔粘连已经成为继发性不孕患者的最常见原因,占继发性不孕症发病原因的8%,它还可导致习惯性流产,试管婴儿植入失败等并发症,严重威胁我国育龄期妇女的生殖健康。
目前临床上治疗宫腔粘连的主要方法为宫腔镜下粘连松解术,术后放置宫内节育器等。但各种预防措施的效果均不尽如人意,治疗后粘连再形成的发生率在所有患者中约为3.1%~23.5%,重度患者中可达20%~62.5%。如果子宫内膜损伤面积过大或完全裸露,即使手术恢复了宫腔形态,内膜也很难再生,恢复功能。为了解决这一难题,生殖专家把目标转移到了目前的研究热点组织工程技术上,自从1993年细胞膜片技术发明以来,从最初昂贵的温度敏感培养基,发展到现在仅在完全培养基中加入活性因子即可诱导细胞重叠生长,从而获得由细胞、细胞外基质构成,为克服上述缺点带来希望。但是如何能有效防止子宫损伤后形成的宫腔粘连,能使细胞膜片具有促进组织再生机制,从而促进子宫内膜伤口愈合的功效目前还没有定论需要进一步研究。
发明内容
为了解决上述问题,本发明的目的一种构建脂肪干细胞膜片的方法及应用,本发明这种方法是一种新的培养体系用于诱导人的脂肪干细胞形成脂肪干细胞膜片,这种方式诱导形成的膜片不仅含有大量的细胞外基质,同时诱导部分干细胞转化为上皮细胞,更利于修复人子宫内膜上皮组织。
本发明的技术方案是:一种构建脂肪干细胞膜片的方法,其特征是:该方法包括如下步骤:
步骤1)选择脂肪干细胞作为种子细胞构建细胞膜片;
步骤2)将子宫内膜细胞用于诱导的共培养细胞;
步骤3)采用化学诱导和共培养的方式构建脂肪干细胞膜片。
所述步骤1)脂肪干细胞:取脂肪组织20ml,用PBS清洗,眼科剪剪碎后加20ml的0.25%的Ι型胶原酶37℃恒温摇床消化60min;加入等量的含10%胎牛血清的ɑ-mem完全培养基终止消化,1000转5min离心,去上清,加10ml含10%胎牛血清的ɑ-mem完全培养基重悬接种在75cm2培养瓶中,48h后换液,脂肪干细胞生长融合达到瓶底面积的80%-90%时胰酶消化传代。
所述步骤2)子宫内膜细胞:取子宫内膜组织用无菌PBS反复冲洗,眼科剪剪去血污组织后,剪碎,加入20ml的0.25%Ι型胶原酶,37℃恒温摇床消化120min,加入等体积的含10%胎牛血清α-MEM完全培养液终止消化,用100目的筛网过滤,将滤液再次使用200目的筛网过滤,收集滤液1000r/min离心10min,弃上清,放入α-MEM完全培养液重悬,1000r/min,再次离心10min,弃上清,α-MEM完全培养液重悬,接种于6孔板中,置于37℃、5%CO2的培养箱中培养,24h后换液,洗去悬浮细胞碎片和杂质,得子宫内膜细胞。
所述步骤3)具体步骤为:将步骤1)的脂肪干细胞按照1*104/cm2密度接种在六孔板中,步骤1)的培养基更换为诱导培养液;孔板中放置transwell小室,小室滤膜孔径为0.8um,小室内按3×103个接种步骤2)子宫内膜细胞,每两天更换诱导培养基,连续培养两周,膜片形成。
所述子宫内膜细胞包括子宫内膜基质细胞和子宫内膜上皮细胞。
所述化学诱导的诱导培养基为诱导培养基为:由膜片培养基和上皮细胞诱导剂组成,其中,膜片培养基为gibco的ɑ-mem培养基添加10%的FBS和100um/ml维生素C;上皮细胞诱导剂为1ⅹ10-7mol/Lβ-雌二醇、10ng/ml TGF-β1、10ng/ml EGF和10ng/ml PDGF-BB。
该方法构建的脂肪干细胞膜片在制备子宫内膜上皮组织修复材料中的应用。
本发明的优点:本发明利用细胞膜片培养基添加外源性因素(TGF-β1,EGF,PDGF-BB,17-β雌二醇)复合子宫内膜细胞共培养,诱导人脂肪干细胞成膜,这个膜片培养体系,诱导成的膜片各上皮标记mRNA表达量上调,免疫荧光显示蛋白CK18表达阳性,提示部分干细胞向上皮细胞转化。这个体系诱导出的膜片在修复子宫内膜上皮方面更有效。
下面通过具体实施例对本发明做进一步详细说明,但不作为对本发明的限定。
附图说明
图1是本发明采用免疫荧光化学方法鉴定子宫内膜细胞鉴定图;
图2是本发明脂肪干细胞膜片形态学观察图;图2的A为镜下观察膜片中的细胞呈长梭形重叠生长,图2的B为成熟的细胞膜片;
图3是本发明构建脂肪干细胞膜片组织学形态图,其中,图3中的a为扫描电镜放大300倍观察细胞轮廓,图3中的b为扫描电镜放大5000倍观察细胞轮廓;
图4为免疫荧光化学方法鉴定不同处理后的ADSCs第1组和第2组的对照图;
图5为免疫荧光化学方法鉴定不同处理后的ADSCs第3组和第4组的对照图;
图6为ADSCs上皮细胞标记mRNA表达情况。
具体实施方式
实施例1
一种构建脂肪干细胞膜片的方法,包括如下步骤:
步骤1)选择脂肪干细胞作为种子细胞构建细胞膜片;
步骤2)将子宫内膜细胞用于诱导的共培养细胞;
步骤3)采用化学诱导和共培养的方式构建脂肪干细胞膜片。
实施例2
一种构建脂肪干细胞膜片的方法,包括如下步骤:
步骤1)选择脂肪干细胞作为种子细胞构建细胞膜片;所述脂肪干细胞:取脂肪组织20ml,用PBS清洗,眼科剪剪碎后加20ml的0.25%的Ι型胶原酶37℃恒温摇床消化60min;加入等量的含10%胎牛血清的ɑ-mem完全培养基终止消化,1000转5min离心,去上清,加10ml含10%胎牛血清的ɑ-mem完全培养基重悬接种在75cm2培养瓶中,48h后换液,脂肪干细胞生长融合达到瓶底面积的80%-90%时胰酶消化传代。将脂肪干细胞简写为ADSCs。
步骤2)将子宫内膜细胞用于诱导的共培养细胞;所述子宫内膜细胞:取子宫内膜组织用无菌PBS反复冲洗,眼科剪剪去血污组织后,剪碎,加入20ml的0.25%Ι型胶原酶,37℃恒温摇床消化120min,加入等体积的含10%胎牛血清α-MEM完全培养液终止消化,用100目的筛网过滤,将滤液再次使用200目的筛网过滤,收集滤液1000r/min离心10min,弃上清,放入α-MEM完全培养液重悬,1000r/min,再次离心10min,弃上清,α-MEM完全培养液重悬,接种于6孔板中,置于37℃、5%CO2的培养箱中培养,24h后换液,洗去悬浮细胞碎片和杂质,得子宫内膜细胞。见图1,采用免疫荧光化学方法鉴定子宫内膜细胞显示:角蛋白CK18和波形蛋白Vimentin标记阳性,ERα标记表达阳性,PR标记表达弱阳性。证明上述分离培养的细胞为子宫内膜细胞。
步骤3)采用化学诱导和共培养的方式构建脂肪干细胞膜片;所述步骤3)具体步骤为:将步骤1)的脂肪干细胞按照1*104/cm2密度接种在六孔板中,步骤1)的培养基更换为诱导培养液;孔板中放置transwell小室,小室滤膜孔径为0.8um,小室内按3×103个接种步骤2)子宫内膜细胞,每两天更换诱导培养基,连续培养两周,膜片形成。Transwell小室膜上接种子宫内膜细胞,ADSCs接种于下层普通培养板,整个培养体系的培养液和可溶性因子可自由通过。
ADSCs使用细胞膜片诱导培养液连续培养10-14天后就可获得白色膜状的细胞膜片,镜下观察膜片中的细胞呈长梭形重叠生长(见图2A),成熟的细胞膜片可用细胞刀轻轻刮下,具有一定韧性和弹性(见图2B)
见图3为扫描电镜观察,整个膜片表面光滑,图3中的a为放大300倍隐约可见细胞轮廓,图3中的b为放大5000倍能看到细胞与细胞之间连接成片的的胶原蛋白,以及膜片是由多层细胞叠加形成。
所述子宫内膜细胞包括子宫内膜基质细胞和子宫内膜上皮细胞。
所述化学诱导的诱导培养基为诱导培养基为:由膜片培养基和上皮细胞诱导剂组成,其中,膜片培养基为gibco的ɑ-mem培养基添加10%的FBS和100um/ml维生素C;上皮细胞诱导剂为1ⅹ10-7mol/Lβ-雌二醇、10ng/ml TGF-β1、10ng/ml EGF和10ng/ml PDGF-BB。
上述百分数均为质量百分比浓度。
比较例:
将不同的培养细胞及培养基进行比较(见表1),表1中的对照培养液为5%FBS+DMEM,表1中的诱导分化培养液为本发明的诱导培养基;采用q-RT-PCR方法检测上述处理后5天的ADSCs的上皮细胞标记CK7,CK18,CK19,EMA mRNA表达,免疫荧光化学方法检测各组处理5天后的下层ADSCs角蛋白的表达见图4和图5。
表1
分组 | 培养细胞 | 培养基 |
第1组 | ADSCs | 对照培养液 |
第2组 | ADSCs | 诱导分化培养液 |
第3组 | ADSCs+子宫内膜细胞 | 对照培养液 |
第4组 | ADSCs+子宫内膜细胞 | 诱导分化培养液 |
ADSCs经过上述不同4组处理后,免疫荧光化学方法鉴定经过不同处理的ADSCs角蛋白表达:如图4所示,1、2组角蛋白CK18表达阴性;如图5所示,3、4组角蛋白CK18表达阳性但第4组诱导后的ADSCs形态更接近上皮细胞形态。如图6所示,q-RT-PCR方法检测ADSCs按上述处理5天后各组上皮细胞标记表达发现,CK18mRNA表达量在各组中呈依次表达上升,在第4组表达达到最高,且各组均有差异。CK7、CK19、EMA mRNA在2、3、4组表达量均比第一组表达升高,但后3组无差异。结果与免疫荧光结果一致,说明17β-雌激素,TGF-β1,EGF,PDGf-BB和共培养中的子宫内膜细胞分泌因子的共同作用在促进角蛋白的表达上作用最显著。
结论:1、ADSCs膜片高表达TGFβ1、FGF2、HGF、VEGF和Col1A1等促生长细胞因子,同样高表达OCT4、NANOG等干性基因。2、人ADSCs在一定的条件下体外可向子宫内膜上皮方向分化。外源性因素(TGF-β1,EGF,PDGF-BB,17-β雌二醇)和子宫内膜细胞分泌因子的联合作用下,其在促进ADSCs向子宫内膜上皮细胞方向分化的过程中作用最显著。
本发明利用膜片培养基添加外源性因素(TGF-β1,EGF,PDGF-BB,17-β雌二醇)复合子宫内膜细胞共培养,诱导人脂肪干细胞成膜,这个膜片培养体系,诱导成的膜片各上皮标记mRNA表达量上调,免疫荧光显示蛋白CK18表达阳性,提示部分干细胞向上皮细胞转化。该方法诱导出的膜片在修复子宫内膜上皮方面更有效。该方法构建的脂肪干细胞膜片能够在制备子宫内膜上皮组织修复材料中应用。
本实施例没有详细叙述的部分和英文缩写属本行业的公知常识,在网上可以搜索到,这里不一一叙述。
Claims (4)
1.一种构建脂肪干细胞膜片的方法,其特征是:该方法包括如下步骤:
步骤1)选择脂肪干细胞作为种子细胞构建细胞膜片;
步骤2)将子宫内膜细胞用于诱导的共培养细胞;
步骤3)采用化学诱导和共培养的方式构建脂肪干细胞膜片;具体步骤为:将步骤1)的脂肪干细胞按照1×104/cm2密度接种在六孔板中,步骤1)的培养基更换为诱导培养基;孔板中放置transwell小室,小室滤膜孔径为0.8um,小室内按3×103个接种步骤2)子宫内膜细胞,每两天更换诱导培养基,连续培养两周,膜片形成;
所述子宫内膜细胞包括子宫内膜基质细胞和子宫内膜上皮细胞;所述化学诱导的诱导培养基由膜片培养基和上皮细胞诱导剂组成,其中,膜片培养基为gibco的ɑ-MEM培养基添加10%的FBS和100um/ml维生素C;上皮细胞诱导剂为1×10-7 mol/L β-雌二醇、10 ng/mlTGF-β1、 10 ng/ml EGF和10 ng/ml PDGF-BB。
2.根据权利要求1所述的一种构建脂肪干细胞膜片的方法,其特征是:所述步骤1)脂肪干细胞:取脂肪组织20ml,用PBS清洗,眼科剪剪碎后加20ml的0.25%的Ι型胶原酶37℃恒温摇床消化60min;加入等量的含10%胎牛血清的ɑ-MEM完全培养基终止消化,1000r/min离心5min,去上清,加10ml含10%胎牛血清的ɑ-MEM完全培养基重悬接种在75cm2培养瓶中,48h后换液,脂肪干细胞生长融合达到瓶底面积的80%-90%时胰酶消化传代。
3.根据权利要求1所述的一种构建脂肪干细胞膜片的方法,其特征是:所述步骤2)子宫内膜细胞:取子宫内膜组织用无菌PBS反复冲洗,眼科剪剪去血污组织后,剪碎,加入20ml的0.25%Ι型胶原酶,37℃恒温摇床消化120 min,加入等体积的含10%胎牛血清α-MEM完全培养液终止消化,用100目的筛网过滤,将滤液再次使用200目的筛网过滤,收集滤液1000r/min离心10min,弃上清,放入α-MEM完全培养液重悬,1000r/min,再次离心10min,弃上清,α-MEM完全培养液重悬,接种于6孔板中,置于37℃、5% CO2的培养箱中培养,24 h后换液,洗去悬浮细胞碎片和杂质,得子宫内膜细胞。
4.一种权利要求1所述的构建脂肪干细胞膜片的方法构建的脂肪干细胞膜片在制备子宫内膜上皮组织修复材料中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810235273.2A CN108486038B (zh) | 2018-03-21 | 2018-03-21 | 一种构建脂肪干细胞膜片的方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810235273.2A CN108486038B (zh) | 2018-03-21 | 2018-03-21 | 一种构建脂肪干细胞膜片的方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108486038A CN108486038A (zh) | 2018-09-04 |
CN108486038B true CN108486038B (zh) | 2021-08-27 |
Family
ID=63318966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810235273.2A Expired - Fee Related CN108486038B (zh) | 2018-03-21 | 2018-03-21 | 一种构建脂肪干细胞膜片的方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108486038B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111621474A (zh) * | 2019-02-28 | 2020-09-04 | 京东方科技集团股份有限公司 | 间充质干细胞膜片及其制备方法 |
CN111849881A (zh) * | 2020-07-16 | 2020-10-30 | 上海赛傲生物技术有限公司 | 一种基于温皿制备人源脂肪干细胞膜片的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2393916A2 (en) * | 2009-02-04 | 2011-12-14 | Endgenitor Technologies, Inc. | Therapeutic use of specialized endothelial progenitor cells |
CN104694468A (zh) * | 2013-12-10 | 2015-06-10 | 中国科学院大连化学物理研究所 | 一种用于筛选抗骨质疏松药物的细胞共培养模型及其应用 |
CN105169485A (zh) * | 2015-07-29 | 2015-12-23 | 西安芙金细胞科技有限公司 | 一种组织工程子宫内膜及其制备方法 |
WO2017147600A1 (en) * | 2016-02-25 | 2017-08-31 | Briacell Therapeutics Corp. | Whole-cell cancer vaccines and methods for selection thereof |
CN107760646A (zh) * | 2012-09-04 | 2018-03-06 | 人类起源公司 | 组织产生方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2956147B1 (en) * | 2013-02-12 | 2022-08-24 | Reneuron Limited | Method of producing microparticles |
CN109852582B (zh) * | 2017-11-30 | 2021-04-30 | 北京世纪劲得生物技术有限公司 | 一种子宫内膜干细胞的分离培养方法及其专用培养基 |
-
2018
- 2018-03-21 CN CN201810235273.2A patent/CN108486038B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2393916A2 (en) * | 2009-02-04 | 2011-12-14 | Endgenitor Technologies, Inc. | Therapeutic use of specialized endothelial progenitor cells |
CN107760646A (zh) * | 2012-09-04 | 2018-03-06 | 人类起源公司 | 组织产生方法 |
CN104694468A (zh) * | 2013-12-10 | 2015-06-10 | 中国科学院大连化学物理研究所 | 一种用于筛选抗骨质疏松药物的细胞共培养模型及其应用 |
CN105169485A (zh) * | 2015-07-29 | 2015-12-23 | 西安芙金细胞科技有限公司 | 一种组织工程子宫内膜及其制备方法 |
WO2017147600A1 (en) * | 2016-02-25 | 2017-08-31 | Briacell Therapeutics Corp. | Whole-cell cancer vaccines and methods for selection thereof |
Non-Patent Citations (3)
Title |
---|
Partial regeneration of uterine horns in rats through adipose-derived stem cell sheets;Huijun Sun等;《Biology of Reproduction》;20180620;第99卷(第5期);第1057-1069页 * |
人脂肪干细胞膜片的构建及其对子宫内膜修复功能的初步研究;杨芳;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20190515(第5期);第E068-46页 * |
人脂肪干细胞膜片的构建及其生物学特性初探;杨芳等;《解放军医学院学报》;20180228;第39卷(第2期);第144页摘要、第145页第3、7节及第148页右栏第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN108486038A (zh) | 2018-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shiroyanagi et al. | Transplantable urothelial cell sheets harvested noninvasively from temperature-responsive culture surfaces by reducing temperature | |
CN103705984B (zh) | 胶原支架复合骨髓间充质干细胞制备方法及应用 | |
Catala et al. | Approaches for corneal endothelium regenerative medicine | |
JPWO2005087286A1 (ja) | 生体組織シート及びその作製方法、並びに同シートを用いる移植方法 | |
CN108486038B (zh) | 一种构建脂肪干细胞膜片的方法及应用 | |
WO2014104366A1 (ja) | ヒト角膜内皮細胞シート | |
CN107629998A (zh) | 一种用月经血来源的干细胞体外修复受损子宫内膜的模型 | |
Sun et al. | Development of a closed bioreactor system for culture of tissue-engineered skin at an air–liquid interface | |
JP2006187281A (ja) | ヒト角膜内皮細胞由来の前駆細胞、細胞凝集体及びそれら作製方法、並びに前駆細胞および細胞凝集体の移植方法 | |
Dhamodaran et al. | One for all: a standardized protocol for ex vivo culture of limbal, conjunctival and oral mucosal epithelial cells into corneal lineage | |
WO2007043255A1 (ja) | 培養角膜内皮シート及びその作製方法 | |
Kobayashi et al. | Stromal–epithelial interaction study: The effect of corneal epithelial cells on growth factor expression in stromal cells using organotypic culture model | |
Jiang et al. | Using human epithelial amnion cells in human de-epidermized dermis for skin regeneration | |
Wang et al. | Human acellular amniotic matrix with previously seeded umbilical cord mesenchymal stem cells restores endometrial function in a rat model of injury | |
Witt et al. | Decellularized porcine conjunctiva as an alternative substrate for tissue-engineered epithelialized conjunctiva | |
CN109517784B (zh) | 一种类角膜上皮细胞、组织工程化角膜上皮及制备与应用 | |
JPWO2005087285A1 (ja) | 角膜上皮シート及びその作製方法、並びに同シートを用いる移植方法 | |
Hong et al. | Human conjunctival epithelial sheets grown on poly (lactic-co-glycolic) acid membranes and cocultured with human tenon's fibroblasts for corneal repair | |
CN108342322A (zh) | 建立原代人子宫内膜上皮细胞气液相培养模型的方法 | |
CN110408673A (zh) | 研究Hsa_circ_0111659在WJ-MSCs修复ESC中的作用机制的方法 | |
JPWO2007091409A1 (ja) | 組織幹細胞由来フィーダー細胞 | |
CN110951672B (zh) | 一种小鼠子宫内膜上皮细胞及其3d分化培养物模型的构建方法 | |
CN109312301B (zh) | 用于制备培养上皮细胞片的方法 | |
JP2009225675A (ja) | 上皮系細胞シートの作製のための同種皮膚由来フィーダー細胞 | |
CN117384833A (zh) | 一种大鼠牙槽骨组织来源的凋亡囊泡的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210827 |